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The in vitro activities of 16 antimicrobial agents against 86 strains of Corynebacterium striatum were eval-
uated by microdilution using cation-adjusted Mueller-Hinton broth. MICs at which 90% of strains were inhib-
ited were 0.06 mg/ml for teicoplanin, 1 mg/ml for vancomycin, 0.03 to 8 mg/ml for b-lactams, 8 mg/ml for spar-
floxacin, 16 mg/ml for ciprofloxacin, 16/304 mg/ml for co-trimoxazole (trimethoprim-sulfamethoxazole), 64
mg/ml for tetracycline, 128 mg/ml for gentamicin, and >128 mg/ml for amikacin, erythromycin, and rifampin.
Information on the susceptibility of coryneform bacteria to
antimicrobial agents is scarce (1). Most of the reports have
referred to Corynebacterium jeikeium or C. urealyticum (2, 3,
11, 13). The activity of particular antimicrobial groups, i.e.,
fluoroquinolones (5), and studies comparing different method-
ologies (4) have also been reported. Soriano et al. recently
reported the activity of 18 antimicrobial agents against 265
strains of Corynebacterium spp. and other non-spore-forming
gram-positive rods, but for some species, including C. striatum,
a limited number of strains was evaluated (14).
While studying the etiological role of coryneform bacteria in
human infections, our group has recognized C. striatum as an
important cause of both colonization and infection in humans
(8). In a previous report (7), data on the susceptibility testing
of 31 strains of C. striatum by disk diffusion were presented.
The aim of this study is to extend these preliminary data by
determining MICs of 16 antimicrobial agents against 86 strains
of C. striatum isolated from clinical samples.
(This work was presented at the 35th Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy, San Fran-
cisco, Calif., 17 to 20 September 1995 [6].)
Eighty-six strains of C. striatum isolated in the period be-
tween January 1991 to October 1994 from clinical samples of
different patients at the University Hospital V. Macarena,
Seville, Spain, were studied.
Fifty-nine strains were isolated from wound exudates, seven
from catheter tips, seven from bronchial aspirates, three from
urine, two from blood cultures, two from abscesses, and six
from other origins. The first 24 organisms were identified with
all conventional tests, the API CORYNE system, and cellular
fatty acids profiles, as previously described (7). The remaining
62 strains were identified with the API CORYNE system.
Hydrolysis of tyrosine, morphology of the organism in gram
stain, and colonial morphology were additionally assessed to
confirm the identification of these 62 strains (7).
After identification, bacteria were maintained in 10% glyc-
erol in tryptic soy broth at 2708C until they were used. Staph-
ylococcus aureusATCC 29213 and Enterococcus faecalisATCC
29212 were used as control strains.
An in-house microdilution method was used in accordance
with the NCCLS guidelines (9). Although Mueller-Hinton
broth containing 0.5% Tween 80 has been previously used in
our laboratory (4, 5) for susceptibility studies of coryneform
bacteria, cation-adjusted Mueller-Hinton broth (CaMHB) was
used in this study, since in preliminary experiments we ob-
served that it allows for sufficient growth of C. striatum (data
not shown). The following antimicrobial agents were used as
powders of known potency: penicillin G (Sigma, St. Louis,
Mo.), ampicillin (Smith-Kline Beecham, Madrid, Spain), cefa-
zolin (Sigma), cefuroxime (Sigma), cefotaxime (Hoechst, Bar-
celona, Spain), imipenem (Merck Sharp & Dohme, Madrid,
Spain), gentamicin (Sigma), amikacin (Bristol Myers-Squibb,
Madrid, Spain), erythromycin (Sigma), co-trimoxazole (Gal-
loso, Madrid, Spain), tetracycline (Sigma), rifampin (Sigma),
vancomycin (Lilly SA, Madrid, Spain), teicoplanin (Merrell
Dow España, Madrid, Spain), ciprofloxacin (Bayer AG, Bar-
celona, Spain), and sparfloxacin (Rhône Poulenc Europe,
Antony, France). A range of 0.06 to 128 mg/ml for penicillin,
ampicillin, cefazolin, cefuroxime, cefotaxime, gentamicin, ami-
kacin, erythromycin, tetracycline, and rifampin, 0.015 to 16
mg/ml for imipenem, vancomycin, teicoplanin, ciprofloxacin,
and sparfloxacin, and 0.015 and 0.297 (trimethoprim-sulfame-
thoxazole) to 16 and 304 mg/ml for co-trimoxazole were tested.
Bacteria from cultures grown on Columbia agar with 5% sheep
blood for 20 to 24 h were suspended in CaMHB to a concen-
tration of 108 CFU/ml. This suspension was diluted to obtain
5 3 104 CFU per well. The final volume in each well of the
microtiter plate was 100 ml. Once inoculated, plates were in-
cubated at 358C for 18 h. The MIC was determined to be the
lowest concentration of antimicrobial agent that inhibited vis-
ible growth.
Most of the studies on susceptibility testing of coryneform
bacteria describe antibiograms of the fastidious species C.
jeikeium or C. urealytium, both of which frequently require an
enriched medium (i.e., one containing blood or Tween 80) to
grow. In this study, we observed that the nonfastidious species
C. striatum grows well in CaMHB after overnight incubation.
In our opinion, this medium should be considered for suscep-
tibility testing of all nonfastidious coryneform bacteria. The
MIC (range and MICs for 50% [MIC50] and for 90% [MIC90]
of isolates tested) of the different antimicrobial agents evalu-
ated are presented in Table 1.
MIC90s were #1 mg/ml for penicillin, cefazolin, imipenem,
vancomycin, and teicoplanin.
MIC90s of teicoplanin were two to four dilution steps lower
than those of vancomycin. Garcı́a-Rodrı́guez et al. also showed
a lower MIC90 of teicoplanin than that of vancomycin against
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C. urealyticum (2), although other authors have observed sim-
ilar values for both antimicrobial agents against C. urealyticum
and C. jeikeium (11). MIC90s of b-lactams ranged from 0.03
mg/ml (imipenem) to 8 mg/ml (cefotaxime). None of the strains
produced b-lactamase, as determined by the nitrocefin test
(10). These results confirm the in vitro activity of b-lactams
against C. striatum, as has been previously described using the
disk diffusion assay (6). Amikacin was $4 times more active
than gentamicin against 51% of the strains. Gentamicin was
$4 times more active than amikacin against 7% of the strains.
Both aminoglycosides had low activity (MIC .128 mg/ml)
against 30% of the strains. Sparfloxacin was more active than
ciprofloxacin against C. striatum, yielding MICs one or more
dilution steps lower against 51% of the strains. We have pre-
viously reported that new fluoroquinolones are more active
than ciprofloxacin and sparfloxacin against C. striatum: clina-
floxacin had an MIC50 of 0.125 and an MIC90 of 1 mg/ml (5).
Co-trimoxazole, tetracycline, erythromycin, and rifampin had
poor activity against C. striatum; less than 50% of the strains
were inhibited by 16/304 mg/ml (trimethoprim-sulfamethox-
azole), 16, 4, and .128 mg/ml, respectively, of these agents.
To the best of our knowledge, there is only one study (14) in
which the susceptibility of C. striatum to several antimicrobial
agents was quantitatively determined using a representative
number of strains (11 isolates). There is a good overall agree-
ment between this study and ours, but differences have been
observed for rifampin, ciprofloxacin, and gentamicin. The
MIC50 of rifampin and ciprofloxacin are higher in our study
(.128 and 4 mg/ml) than in the study by Soriano et al. (2 and
0.25 mg/ml) (15). Similarly, the MIC90 of gentamicin was also
higher in our study (128 mg/ml versus 2 mg/ml). The larger
number of strains in our study could be related to a higher
probability of finding different antibiotypes of C. striatum, but
it is difficult to determine the basis (i.e., temporal, geographi-
cal, etc.) accounting for these differences.
There are not breakpoints from the NCCLS to assign inter-
pretative categories for coryneform bacteria. Considering
MICs of the antimicrobial agents evaluated against C. striatum
above the intermediate breakpoint for staphylococci as a ref-
erence of decreased in vitro antimicrobial activity, we have ob-
served little simultaneous activity of several agents against some
C. striatum strains. The most common phenotypes included
decreased susceptibility to erythromycin, tetracycline, cotri-
moxazole, fluoroquinolones, and rifampin (38% of strains); to
erythromycin, tetracycline, cotrimoxazole, fluoroquinolones, and
aminoglycosides (14% of the strains); and to erythromycin,
tetracycline, cotrimoxazole, fluoroquinolones, and rifampin
(8% of the strains).
The molecular basis of the mechanisms of resistance to
antimicrobial agents in C. striatum is poorly known. Roberts et
al. (12) reported that 15 of 17 strains carried the ermCd gene
and were resistant or intermediately resistant to erythromycin;
13 strains also carried the tetM gene and were tetracycline
resistant. New studies are needed in order to obtain informa-
tion about the mechanisms of resistance of C. striatum to other
antimicrobial agents commonly used in clinics, including fluo-
roquinolones, aminoglycosides, co-trimoxazole, and rifampin.
As the clinical relevance of C. striatum is increasingly rec-
ognized (7, 8, 15), the data obtained in this study may support
therapeutic options against the infections caused by this organ-
ism, which could allow the establishment of breakpoints for the
assignment of in vitro activity data to interpretative clinical
categories.
We gratefully acknowledge the help of Judith Winstanley for her
contribution in the identification of C. striatum and of Patricia Hidalgo
and Janet Dawson for manuscript preparation.
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TABLE 1. In vitro activity of 16 antimicrobial agents against 86









Penicillin #0.06–2 0.25 0.5
Ampicillin ,0.06–8 1 2
Cefazolin #0.06–8 0.5 1
Cefuroxime #0.06–16 1 2
Cefotaxime #0.06–32 2 8
Imipenem #0.015–4 0.015 0.03
Gentamicin #0.06–128 1 128
Amikacin #0.015–.128 0.125 .128
Erythromycin #0.06–.128 4 .128
Tetracycline #0.06–64 16 64
Co-trimoxazole #0.015–.16 16 16
Rifampin #0.06–.128 .128 .128
Vancomycin 0.125–2 0.25 1
Teicoplanin 0.06–4 0.06 0.06
Ciprofloxacin #0.015–.16 4 16
Sparfloxacin #0.008–.16 2 8
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